Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Richard A. Larson*, Sumithra J. Mandrekar, Lucas J. Huebner, Ben L. Sanford, Kristina Laumann, Susan Geyer, Clara D. Bloomfield, Christian Thiede, Thomas W. Prior, Konstanze Döhner, Guido Marcucci, Maria Teresa Voso, Rebecca B. Klisovic, Ilene Galinsky, Andrew H. Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger NiederwieserFrederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Hartmut Döhner, Richard M. Stone

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

INIS